Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice: A Prospective Phase IV, Multicentre, Pan-Hellenic Observational Cohort Study

NCT02594436 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT02594436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02594436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice: A Prospective Phase IV, Multicentre, Pan-Hellenic Observational Cohort Study
Lead sponsor
LEO Pharma
Phase
Observational
Overall status
Completed
Start date
December 1, 2015
Completion date
November 30, 2017
Enrollment
440 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis